Pharmacodynamic results
PD
A significant decrease in free sIL‐33 levels was seen in GSK3772847 cohorts as compared with placebo cohorts; this decrease was similar across ethnicities in cohorts 2, 3, and 4 over the study duration. The maximum decrease from baseline in free sIL‐33 levels (geometric mean) was >93% with GSK3772847 70 mg SC and >95% with GSK3772847 140 mg SC across all injection sites (Figure Median free soluble IL‐33 levels by dose, injection site, and placebo (a, b) and total soluble IL‐33 levels by dose, injections site, and placebo (c, d) (PD population). Error bars represent minimum and maximum values. PD, pharmacodynamic; SC subcutaneousMedian free and total soluble IL‐33 levels by cohort and placebo for 140 mg SC GSK3772847 dose (PD population). Error bars represent minimum and maximum values. IL‐33, interleukin 33; PD, pharmacodynamic; SC subcutaneous